Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Heart Failure Reviews
Published in: Heart Failure Reviews 5/2016

Open Access 01-09-2016

A review on B-type natriuretic peptide monitoring: assays and biosensors

Authors: Rita Maalouf, Steven Bailey

Published in: Heart Failure Reviews | Issue 5/2016

Login to get access

Abstract

Since its discovery in 1988, B-type natriuretic peptide (BNP) has been recognized as a powerful cardiovascular biomarker for a number of disease states, specifically heart failure. Concurrent with such a discovery, much effort has been allocated to the precise monitoring of physiological BNP levels. Thus, it can be used to guide the therapy of heart failure and determine the patient’s stage of disease. Thus, we discuss in this article BNP as a potent biomarker. Subsequently, we will review the progress of biosensing devices as they could be applied to monitor BNP levels as assays, benchtop biosensors and implantable biosensors. The analytical characteristics of commercially available BNP assays are presented. Still emerging as a field, we define four obstacles that present opportunity for the future development of implantable biosensor: foreign body response, sensor renewability, sensitivity and selectivity.
Literature
1.
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti S, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB, American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2015) Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 131:e29–e322CrossRefPubMed
2.
McDonnell B, Hearty S, Leonard P, O’Kennedy R (2009) Cardiac biomarkers and the case for point-of-care testing. Clin Biochem 42:549–561PubMedCrossRef
3.
Moriates C, Maisel A (2010) The utility of biomarkers in sorting out the complex patient. Am J Med 123:393–399PubMedCrossRef
4.
Bozkurt B, Mann DL (2003) Use of biomarkers in the management of heart failure: are we there yet? Circulation 107:1231–1233PubMedCrossRef
5.
Yang Z, Min Zhou D (2006) Cardiac markers and their point-of-care testing for diagnosis of acute myocardial infarction. Clin Biochem 39:771–780PubMedCrossRef
6.
Konstam MA (2007) Natriuretic peptides and cardiovascular events: more than a stretch. JAMA 297:212–214PubMedCrossRef
7.
Caldwell MA, Howie JN, Dracup K (2003) BNP as discharge criteria for heart failure. J Card Fail 9:416–422PubMedCrossRef
8.
Lee DS, Vasan RS (2005) Novel markers for heart failure diagnosis and prognosis. Curr Opin Cardiol 20:201–210PubMedCrossRef
9.
Iqbal N, Wentworth B, Choudhary R, De La Parra Landa A, Kipper B, Fard A, Maisel AS (2012) Cardiac biomarkers: new tools for heart failure management. Cardiovac Diagn Ther 2:147–164
10.
Panagopoulou V, Deftereos S, Kossyvakis C, Raisakis K, Giannopoulos G, Bouras G, Pyrgakis V, Cleman MW (2013) NTproBNP: an important biomarker in cardiac diseases. Curr Top Med Chem 13:82–94PubMedCrossRef
11.
Motiwala SR, Januzzi JL Jr (2013) The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure. Clin Pharmacol Ther 93:57–67PubMedCrossRef
12.
Coco G, Jerie P (2015) Assessing the benefits of natriuretic peptides-guided therapy in chronic heart failure. Cardiol J 22:5–11CrossRef
13.
Balion C, McKelvie R, Don-Wauchope AC, Santaguida PL, Oremus M, Keshavarz H, Hill SA, Booth RA, Ali U, Brown JA, Bustamam A, Sohel N, Raina P (2014) B-type natriuretic peptide-guided therapy: a systematic review. Heart Fail Rev 19:553–564PubMedCrossRef
14.
Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355:1126–1130PubMedCrossRef
15.
Beck-da-Silva L, de Bold A, Fraser M, Williams K, Haddad H (2005) BNP-guided therapy not better than expert’s clinical assessment for beta-blocker titration in patients with heart failure. Congest Heart Fail 11:248–253PubMedCrossRef
16.
Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, Aupetit JF, Aumont MC, Galinier M, Eicher JC, Cohen-Solal A, Juillère Y (2007) Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 49:1733–1739PubMedCrossRef
17.
Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, Vuillomenet A, Jeker U, Dubach P, Beer H, Yoon SI, Suter T, Osterhues HH, Schieber MM, Hilti P, Schindler R, Brunner-La Rocca HP, Investigators TIME-CHF (2009) BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIMECHF) randomized trial. JAMA 301:383–392PubMedCrossRef
18.
Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, Hamid AK, Nicholls MG, Richards AM (2009) N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNPAssisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 55:53–60PubMedCrossRef
19.
Persson H, Erntell H, Eriksson B, Johansson G, Swedberg K, Dahlström U (2010) Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure—SIGNAL-HF (Swedish Intervention study—guidelines and NT-proBNP AnaLysis in Heart Failure). Eur J Heart Fail 12:1300–1308PubMedCrossRef
20.
Eurlings LW, van Pol PE, Kok WE, van Wijk S, Lodewijks-van der Bolt C, Balk AH, Lok DJ, Crijns HJ, van Kraaij DJ, de Jonge N, Meeder JG, Prins M, Pinto YM (2010) Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol 56:2090–2100PubMedCrossRef
21.
Anguita M, Esteban F, Castillo JC, Mazuelos F, López-Granados A, Arizón JM, Suárez De Lezo J (2010) Usefulness of brain natriuretic peptide levels, as compared with usual clinical control, for the treatment monitoring of patients with heart failure. Med Clin (Barc) 135:435–440CrossRef
22.
Berger R, Moertl D, Peter S, Ahmadi R, Huelsmann M, Yamuti S, Wagner B, Pacher R (2010) N-Terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol 55:645–653PubMedCrossRef
23.
Shah MR, Califf RM, Nohria A, Bhapkar M, Bowers M, Mancini DM, Fiuzat M, Stevenson LW, O’Connor CM (2011) The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. J Card Fail 17:613–621PubMedCrossRef
24.
Karlström P, Alehagen U, Boman K, Dahlström U, UPSTEP-Study Group (2011) Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome. Eur J Heart Fail 13:1096–1103PubMedCrossRef
25.
Januzzi JL Jr, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, Kim HN, Baggish AL, Weiner RB, Chen-Tournoux A, Marshall JE, Moore SA, Carlson WD, Lewis GD, Shin J, Sullivan D, Parks K, Wang TJ, Gregory SA, Uthamalingam S, Semigran MJ (2011) Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 58:1881–1889PubMedCrossRef
26.
Savarese G, Trimarco B, Dellegrottaglie S, Prastaro M, Gambardella F, Rengo G, Leosco D, Perrone-Filardi P (2013) Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLoS ONE 8:e58287PubMedPubMedCentralCrossRef
27.
Sudoh T, Kangawa K, Minamino N, Matsuo H (1988) A new natriuretic peptide in porcine brain. Nature 332:78–81PubMedCrossRef
28.
Sudoh T, Minamino N, Kangawa K, Matsuo H (1988) Brain natriuretic peptide-32: N-terminal six amino acid extended form of brain natriuretic peptide identified in porcine brain. Biochem Biophys Res Commun 155:726–732PubMedCrossRef
29.
Matsuura H, Sato Y, Niwa O, Mizutani F (2005) Electrochemical enzyme immunoassay of a peptide hormone at picomolar levels. Anal Chem 77:4235–4240PubMedCrossRef
30.
Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, Shirakami G, Jougasaki M, Obata K, Yasue H (1991) Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87:1402–1412PubMedPubMedCentralCrossRef
31.
Nakamura S, Naruse M, Naruse K, Kawana M, Nishikawa T, Hosoda S, Tanaka I, Yoshimi T, Yoshihara I, Inagami T (1991) Atrial natriuretic peptide and brain natriuretic peptide coexist in the secretory granules of human cardiac myocytes. Am J Hypertens 4:909–912PubMedCrossRef
32.
Clerico A, Recchia FA, Passino C, Emdin M (2006) Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol 290:H17–H29PubMedCrossRef
33.
De Lemos JA, McGuire DK, Drazner MH (2003) B-type natriuretic peptide in cardiovascular disease. Lancet 362:316–322PubMedCrossRef
34.
Rodeheffer RJ (2004) Measuring plasma B-type natriuretic peptide in heart failure: good to go in 2004? J Am Coll Cardiol 44:740–749PubMed
35.
36.
Vanderheyden M, Bartunek J, Goethals M (2004) Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail 6:261–268PubMedCrossRef
37.
Yamanouchi S, Kudo D, Endo T, Kitano Y, Shinozawa Y (2010) Blood N-terminal proBNP as a potential indicator of cardiac preload in patients with high volume load. Tohoku J Exp Med 221:175–180PubMedCrossRef
38.
39.
40.
41.
Cataliotti A, Boerrigter G, Costello-Boerrigter LC, Schirger JA, Tsuruda T, Heublein DM, Chen HH, Malatino LS, Burnett JC Jr (2004) Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation 109:1680–1685PubMedCrossRef
42.
Brandt I, Lambeir AM, Ketelslegers JM, Vanderheyden M, Scharpe S, De Meester I (2006) Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro Form. Clin Chem 52:82–87PubMedCrossRef
43.
Kroll MH, Srisawasdi P (2007) The clearance of BNP modeled using the NT-proBNP-BNP relationship. Biosystems 88:147–155PubMedCrossRef
44.
Ozaki J, Shimizu H, Hashimoto Y, Itoh H, Nakao K, Inui KI (1999) Enzymatic inactivation of major circulating forms of atrial and brain natriuretic peptides. Eur J Pharmacol 370:307–312PubMedCrossRef
45.
Walther T, Stepan H, Pankow K, Gembardt F, Faber R, Schultheiss HP, Siems WE (2004) Relation of ANP and BNP to their N-terminal fragments in fetal circulation: evidence for enhanced neutral endopeptidase activity and resistance of BNP to neutral endopeptidase in the fetus. BJOG 111:452–455PubMedCrossRef
46.
Kenny AJ, Bourne A, Ingram J (1993) Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J 291:83–88PubMedPubMedCentralCrossRef
47.
McCullough PA, Omland T, Maisel AS (2003) B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med 4:72–80PubMed
48.
Norman JA, Little D, Bolgar M, Di Donato G (1991) Degradation of brain natriuretic peptide by neutral endopeptidase: species specific sites of proteolysis determined by mass spectrometry. Biochem Biophys Res Commun 175:22–30PubMedCrossRef
49.
Shimizu H, Masuta K, Aono K, Asada H, Sasakura K, Tamaki M, Sugita K, Yamada K (2002) Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta 316:129–135PubMedCrossRef
50.
Shimizu H, Aono K, Masuta K, Asada H, Misaki A, Teraoka H (2001) Degradation of human brain natriuretic peptide (BNP) by contact activation of blood coagulation system. Clin Chim Acta 305:181–186PubMedCrossRef
51.
Vittorini S, Prontera C, Zucchelli GC, Clerico A (2007) Cardiac natriuretic hormones: methodological aspects. Immuno-Anal Biol Spec 22:236–246
52.
Belenky A, Smith A, Zhang B, Lin S, Despres N, Wu AHB, Bluestein BI (2004) The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. Clin Chim Acta 340:163–172PubMedCrossRef
53.
Seidler T, Pemberton C, Yandle T, Espiner E, Nicholls G, Richard M (1999) The amino terminal regions of proBNP and proANP oligomerise through leucine zipper-like coiled-coil motifs. Biochem Biophys Res Commun 255:495–501PubMedCrossRef
54.
Shimizu H, Masuta K, Asada H, Sugita K, Sairenji T (2003) Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta 334:233–239PubMedCrossRef
55.
Schellenberger U, O’Rear J, Guzzetta A, Jue RA, Protter AA, Stephen Pollitt N (2006) The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch Biochem Biophys 451:160–166PubMedCrossRef
56.
Liang F, O’Rear J, Schellenberger U, Tai L, Lasecki M, Schreiner GF, Apple FS, Maisel AS, Pollitt NS, Protter AA (2007) Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 49:1071–1078PubMedCrossRef
57.
Seferian KR, Tamm NN, Semenov AG, Mukharyamova KS, Tolstaya AA, Koshkina EV, Kara AN, Krasnoselsky MI, Apple FS, Esakova TV, Filatov VL, Katrukha AG (2007) The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin Chem 53:866–873PubMedCrossRef
58.
Davlouros PA, Karatza AA, Xanthopoulou I, Dimitriou G, Georgiopoulou A, Mantagos S, Alexopoulos D (2011) Diagnostic role of plasma BNP levels in neonates with signs of congenital heart disease. Int J Cardiol 147:42–46PubMedCrossRef
59.
Blondé-Cynober F, Morineau G, Estrugo B, Fillie E, Aussel C, Vincent JP (2011) Diagnostic and prognostic value of brain natriuretic peptide (BNP) concentrations in very elderly heart disease patients: specific geriatric cut-off and impacts of age, gender, renal dysfunction, and nutritional status. Arch Gerontol Geriatr 52:106–110PubMedCrossRef
60.
Resnik JL, Hong C, Resnik R, Kazanegra R, Beede J, Bhalla V, Maisel A (2005) Evaluation of B-type natriuretic peptide (BNP) levels in normal and preeclamptic women. Am J Obstet Gynecol 193:450–454PubMedCrossRef
61.
Dhaliwal AS, Deswal A, Pritchett A, Aguilar D, Kar B, Souchek J, Bozkurt B (2009) Reduction in BNP levels with treatment of decompensated heart failure and future clinical events. J Card Fail 15:293–299PubMedCrossRef
62.
Mair J, Falkensammer G, Poelzl G, Hammerer-Lercher A, Griesmacher A, Pachinger O (2007) B-type natriuretic peptide (BNP) is more sensitive to rapid hemodynamic changes in acute heart failure than N-terminal proBNP. Clin Chim Acta 379:163–166PubMedCrossRef
63.
Scott PA, Barry J, Roberts PR, Morgan JM (2009) Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular arrhythmias: a meta-analysis. Eur J Heart Fail 11:958–966PubMedCrossRef
64.
Bhardwaj A, Rehman SU, Mohammed A, Baggish AL, Moore SA, Januzzi JL Jr (2010) Design and methods of the Pro-B Type natriuretic peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Am Heart J 159:532–538PubMedCrossRef
65.
Hasegawa K, Fujiwara H, Doyama K, Miyamae M, Fujiwara T, Suga S, Mukoyama M, Nakao K, Imura H, Sasayama S (1993) Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 88:372–380PubMedCrossRef
66.
Del Ry S, Clerico A, Giannessi D, Andreassi MG, Caprioli R, Iascone MR, Ferrazzi P, Biagini A (2000) Measurement of brain natriuretic peptide in plasma samples and cardiac tissue extracts by means of an immunoradiometric assay method. Scand J Clin Lab Invest 60:81–90PubMedCrossRef
67.
Kono M, Yamauchi A, Tsuji T (1993) An immunoradiometric assay for brain natriuretic peptide in human plasma. Jpn Soc Nucl Med Technol 13:2–7
68.
Yandle T, Richards A, Gilbert A, Fisher S, Holmes S, Espiner E (1993) Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. J Clin Endocrinol Metab 76:832–838PubMed
69.
Wolf M, Juncker D, Michel B, Hunziker P, Delamarche E (2004) Simultaneous detection of C-reactive protein and other cardiac markers in human plasma using micromosaic immunoassays and self-regulating microfluidic networks. Biosens Bioelectron 19:1193–1202PubMedCrossRef
70.
71.
Apple FS, Panteghini M, Ravkilde J, Mair J, Wu AH, Tate J, Pagani F, Christenson RH, Jaffe AS, Committee on Standardization of Markers of Cardiac Damage of the IFCC (2005) Quality specifications for B-type natriuretic peptide assays. Clin Chem 51:486–493PubMedCrossRef
72.
Heublein DM, Huntley BK, Boerrigter G, Cataliotti A, Sandberg SM, Redfield MM, Burnett JC Jr (2007) Immunoreactivity and guanosine 3′,5′-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide. Hypertension 49:1114–1119PubMedCrossRef
73.
Clerico A, Zaninotto M, Prontera C, Giovannini S, Ndreu R, Franzini M, Zucchelli GC, Plebani M, on behalf of SIBIOC (2012) State of the art of BNP and NT-proBNP immunoassays: the cardioormocheck study. Clin Chim Acta 414:112–119PubMedCrossRef
74.
Cauliez B, Santos H, Bauer F, Basuyau JP, Nadolny A, Galpy G (2012) Cross-reactivity with endogenous proBNP from heart failure patients for three commercial BNP immunoassays. Clin Chim Acta 413:337–338PubMedCrossRef
75.
Miller WL, Phelps MA, Wood CM, Schellenberger U, Van Le A, Perichon R, Jaffe AS (2011) Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Cir Heart Fail 4:355–360CrossRef
76.
Tsai SH, Lin YY, Chu SJ, Hsu CW, Cheng SM (2010) Interpretation and use of natriuretic peptides in non-congestive heart failure settings. Yonsei Med J 51:151–163PubMedPubMedCentralCrossRef
77.
Hawkridge AM, Heublein DM, Bergen HR, Cataliotti A, Burnett JC, Muddiman DC (2005) Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. PNAS 102:17442–17447PubMedPubMedCentralCrossRef
78.
Wang J, Hong B, Kai J, Han J, Zou Z, Ahn CH, Kang KA (2009) Mini sensing chip for point-of-care acute myocardial infarction diagnosis utilizing micro-electro-mechanical system and nano-technology. Adv Exp Med Biol 645:101–107PubMedCrossRef
79.
Reach G, Wilson GS (1992) Can continuous glucose monitoring be used for the treatment of diabetes? Anal Chem 64:381A–386APubMed
80.
Leung A, Shankar PM, Mutharasan R (2007) A review of fiber-optic biosensors. Sens Actuators B Chem 125:688–703CrossRef
81.
Vaddiraju S, Tomazos I, Burgess DJ, Jain FC, Papadimitrakopoulos F (2010) Emerging synergy between nanotechnology and implantable biosensors: a review. Biosens Bioelectron 25:1553–1565PubMedCrossRef
82.
Manda V, Bennett TD, Yang Z (2005) Implantable biosensor devices for monitoring cardiac marker molecules. International application No.: PCT/US2004/027958
83.
Matsuura H, Sato Y, Niwa O, Mizutani F (2005) Surface electrochemical enzyme immunoassay for the highly sensitive measurement of B-type natriureric peptide. Sens Actuators B Chem 108:603–607CrossRef
84.
Mizutani F, Matsuura H (2005) Surface electrochemistry for the construction of highly sensitive immunoassay system. Curr Appl Phys 5:98–101CrossRef
85.
Kurita R, Yokota Y, Sato Y, Mizutani F, Niwa O (2006) On-chip enzyme immunoassay of a cardiac marker using a microfluidic device combined with a portable surface plasmon resonance system. Anal Chem 78:5525–5531PubMedCrossRef
86.
Teramura Y, Arima Y, Iwata H (2006) Surface plasmon resonance-based highly sensitive immunosensing for brain natriuretic peptide using nanobeads for signal amplification. Anal Biochem 357:208–215PubMedCrossRef
87.
Mischak RP, Lim GA, Scardina JM (2000) Human brain natriuretic peptides. United States Patent. Patent No.: 6,124,430 A
88.
Prasad S, Selvam AP, Reddy RK, Love A (2013) Silicon nanosensor for diagnosis of cardiovascular proteomic markers. J Lab Autom 18:143–151PubMedCrossRef
89.
Lee I, Luo X, Huang J, Cui XT, Yun M (2012) Detection of cardiac biomarkers using single polyaniline nanowire-based conductometric biosensors. Biosensors 2:205–220PubMedPubMedCentralCrossRef
90.
Hong B, Kai J, Ren Y, Han J, Zou Z, Ahn CH, Kang KA (2008) Highly sensitive rapid, reliable, and automatic cardiovascular disease diagnosis with nanoparticle fluorescence enhancer and mems. Adv Exp Med Biol 614:265–273PubMedCrossRef
91.
Hirsch IB, Armstrong D, Bergenstal RM, Buckingham B, Childs BP, Clarke WL, Peters A, Wolpert H (2008) Clinical application of emerging sensor technologies in diabetes management: consensus guidelines for continuous glucose monitoring (CGM). Diabetes Technol Ther 10:232–244PubMedCrossRef
92.
Vincze G, Barner JC, Lopez D (2004) Factors associated with adherence to self-monitoring of blood glucose among persons with diabetes. Diabetes Educ 30:112–125PubMedCrossRef
93.
Wu AHB (2006) Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J 152:828–834PubMedCrossRef
94.
Goodall TA, Halford WK (1991) Self-management of diabetes mellitus: a critical review. Health Psychol 10:1–8PubMedCrossRef
95.
Hitchcock RW, Sorenson JL (2005) Implantable biosensor system, apparatus and method. United States Patent. Patent No.: US 6,965,791 B1
96.
Pickup JC, Hussain F, Evans ND, Sachedina N (2005) In vivo glucose monitoring: the clinical reality and the promise. Biosens Bioelectron 20:1897–1902PubMedCrossRef
97.
Wilson GS, Gifford R (2005) Biosensors for real-time in vivo measurements. Biosens Bioelectron 20:2388–2403PubMedCrossRef
98.
Heller A, Pishko MV (2001) Subcutaneous glucose electrode. United States Patent. Patent No.: US 6.329,161 B1
99.
Guiseppi-Elie A, Brahim S, Slaughter G, Ward KR (2005) Design of a subcutaneous implantable biochip for monitoring of glucose and lactate. IEEE Sens J 5:345–355CrossRef
100.
Mastrototaro J (1999) The MiniMed continuous glucose monitoring system (CGMS). J Pediatr Endocrinol Metab 3:751–758
101.
Bailey T, Zisser H, Chang A (2009) New features and performance of a next-generation seven-day continuous glucose monitoring system with short lag time. Diabetes Technol Ther 11:749–755PubMedCrossRef
102.
Chia CW, Saudek CD (2004) Glucose sensors: toward closed loop insulin delivery. Endocrinol Metab Clin North Am 33:175–195PubMedCrossRef
103.
Brister M, Saint S, Neale PV, Kline DS, Thrower JP, Masterson S, Codd DS (2010) Transcutaneous analyte sensor. United States Patent. Patent No.: US 7,654,956 B2
104.
Potkay J (2008) Long term, implantable blood pressure monitoring systems. Biomed Microdevices 10:379–392PubMedCrossRef
105.
Chamberlain JJ, Small D (2008) Case study: successful use of a single subcutaneous continuous glucose monitor sensor for 28 days in a patient with type 1 diabetes. Clin Diabetes 26:138–139CrossRef
106.
Garg SK, Voelmle MK, Gottlieb P (2009) Feasibility of 10-day use of a continuous glucose-monitoring system in adults with type 1 diabetes. Diabetes Care 32:436–438PubMedPubMedCentralCrossRef
107.
Mortellaro M, DeHennis A (2014) Performance characterization of an abiotic and fluorescent-based continuous glucose monitoring system in patients with type 1 diabetes. Biosens Bioelectron 61:227–231PubMedCrossRef
108.
Hoss U, Budiman ES, Liu H, Christiansen MP (2013) Continuous glucose monitoring in the subcutaneous tissue over a 14-day sensor wear period. J Diabetes Sci Technol 7:1210–1219PubMedPubMedCentralCrossRef
109.
110.
Bowdle T (2002) Complications of invasive monitoring. Anesthesiol Clin N Am 20:571–588CrossRef
111.
The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (2008) Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 359:1464–1476CrossRef
112.
Vigersky RA, Fonda SJ, Chellappa M, Walker MS, Ehrhardt NM (2012) Short- and long-term effects of real-time continuous glucose monitoring in patients with type 2 diabetes. Diabetes Care 35:32–38PubMedCrossRef
113.
Chow EY, Beier BL, Francino A, Chappell WJ, Irazoqui PP (2009) Toward an implantable wireless cardiac monitoring platform integrated with an FDA-approved cardiovascular stent. J Intervent Cardiol 22:479–487PubMedCrossRef
114.
Shelchuk A (2007) Implantable biosensor and methods for monitoring cardiac health. United States Patent. US Patent 7,223,237 B2
115.
Villaseca EH, Dublin GL, Goedeke SD, Haubrich GJ (2001) Telemetry system for implantable medical devices. United States Patent US Patent 6,169,925 B1
116.
Gifford R, Kehoe JJ, Barnes SL, Kornilayev BA, Alterman MA, Wilson GS (2006) Protein interactions with subcutaneously implanted biosensors. Biomaterials 27:2587–2598PubMedCrossRef
117.
Wisniewski N, Reichert M (2000) Methods for reducing biosensor membrane biofouling. Colloids Surf B Biointerfaces 18:197–219PubMedCrossRef
118.
Gant RM, Abraham AA, Hou Y, Cummins BM, Grunlan MA, Coté GL (2010) Design of a self-cleaning thermoresponsive nanocomposite hydrogel membrane for implantable biosensors. Acta Biomater 6:2903–2910PubMedCrossRef
119.
Adiga SP, Jin C, Larry A, Curtiss LA, Monteiro-Riviere NA, Narayan RJ (2009) Nanoporous membranes for medical and biological applications. Wiley Interdiscip Rev Nanomed Nanobiotechnol 1:568–581PubMedPubMedCentralCrossRef
120.
Abraham AA, Fei R, Coté GL, Grunlan MA (2013) Self-cleaning membrane to extend the lifetime of an implanted glucose biosensor. ACS Appl Mater Interfaces 5:12832–12838PubMedPubMedCentralCrossRef
121.
Brault ND, Gao C, Xue H, Piliarik M, Homola J, Jiang S, Yu Q (2010) Ultra-low fouling and functionalizable zwitterionic coatings grafted onto SiO2 via a biomimetic adhesive group for sensing and detection in complex media. Biosens Bioelectron 25:2276–2282PubMedCrossRef
122.
Ligler FS, Gaber BP, Kusterbeck AW, Wemhoff GA (2001) Flow immunosensor apparatus. United States Patent. Patent No.: US 6,245,296 B1
123.
Cooper CGF, MacDonald JC, Soto E, McGimpsey WG (2004) Non-covalent assembly of a photoswitchable surface. J Am Chem Soc 126:1032–1033PubMedCrossRef
124.
125.
Delorme N, Bardeau JF, Bulou A, Poncin-Epaillard F (2005) Azobenzene-containing monolayer with photoswitchable wettability. Langmuir 21:12278–12282PubMedCrossRef
126.
Lahann J, Mitragotri S, Tran TN, Kaido H, Sundaram J, Choi IS, Hoffer S, Somorjai GA, Langer R (2003) A reversibly switching surface. Science 299:371–374PubMedCrossRef
127.
Weissmuller J, Viswanath RN, Kramer D, Zimmer P, Wurschum R, Gleiter H (2003) Charge-induced reversible strain in a metal. Science 300:312–315PubMedCrossRef
128.
Hiramatsu H, Osterloh FE (2003) pH-controlled assembly and disassembly of electrostatically linked CdSe–SiO2 and Au–SiO2 nanoparticle clusters. Langmuir 19:7003–7011CrossRef
129.
130.
Matthews JR, Tuncel DNS, Jacobs RMJ, Bain CD, Anderson HL (2003) Surfaces designed for charge reversal. J Am Chem Soc 125:6428–6433PubMedCrossRef
131.
Albrecht T, Armbruster S, Keller S, Strobl G (2001) Kinetics of reversible surface crystallization and melting in poly(ethylene oxide): effect of crystal thickness observed in the dynamic heat capacity. Eur Phys J E 6:237–243CrossRef
132.
Liu Y, Mu L, Liu B, Zhang S, Yang P, Kong J (2004) Controlled protein assembly on a switchable surface. Chem Commun 10:1194–1195CrossRef
133.
Chua JH, Chee RE, Agarwal A, Wong SM, Zhang GJ (2009) Label-free electrical detection of cardiac biomarker with complementary metal-oxide semiconductor-compatible silicon nanowire sensor arrays. Anal Chem 81:6266–6627PubMedCrossRef
Metadata
Title
A review on B-type natriuretic peptide monitoring: assays and biosensors
Authors
Rita Maalouf
Steven Bailey
Publication date
01-09-2016
Publisher
Springer US
Published in
Heart Failure Reviews / Issue 5/2016
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI
https://doi.org/10.1007/s10741-016-9544-9

Other articles of this Issue 5/2016

Heart Failure Reviews 5/2016 Go to the issue

OriginalPaper

Effect of continuous positive airway pressure treatment on pulmonary artery pressure in patients with isolated obstructive sleep apnea: a meta-analysis

OriginalPaper

Remote ischaemic conditioning and remodelling following myocardial infarction: current evidence and future perspectives

OriginalPaper

Neurohormonal activation and pharmacological inhibition in pulmonary arterial hypertension and related right ventricular failure

OriginalPaper

Mitochondrial pathways to cardiac recovery: TFAM

OriginalPaper

Mitochondrial DNA repair: a novel therapeutic target for heart failure

OriginalPaper

Effect of cardiac pacing on sleep-related breathing disorders: a systematic review

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits